{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:44:10Z","timestamp":1785890650662,"version":"3.56.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T00:00:00Z","timestamp":1777161600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006364","name":"French National Cancer Institute","doi-asserted-by":"publisher","award":["PHRC-K23- 059"],"award-info":[{"award-number":["PHRC-K23- 059"]}],"id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014630","name":"Minist\u00e8re des Solidarit\u00e9s et de la Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014630","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.dld.2026.04.016","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T20:24:30Z","timestamp":1779481470000},"page":"899-905","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dihydropyrimidine dehydrogenase phenotype-guided dose individualization of fluoropyrimidine in gastrointestinal cancers: PRODIGE100-UCGI48-FUDOSE phase II study"],"prefix":"10.1016","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-5735-506X","authenticated-orcid":false,"given":"G.M.","family":"Camilleri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Loriot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Le","family":"Teuff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1207-0383","authenticated-orcid":false,"given":"F.","family":"Thuillier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8284-3743","authenticated-orcid":false,"given":"O.","family":"Bouche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Narjoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9105-6346","authenticated-orcid":false,"given":"M. Ben","family":"Abdelghani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Herve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Corbinais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Locher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5093-0212","authenticated-orcid":false,"given":"T.","family":"Lecomte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Villemin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Tougeron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9211-4707","authenticated-orcid":false,"given":"C.","family":"Lepage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Peytier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AS","family":"Moussaddaq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0525-0423","authenticated-orcid":false,"given":"O.","family":"Dubreuil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Mabro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Desrame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. De Sousa","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Boige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2026.04.016_bib0001","doi-asserted-by":"crossref","first-page":"330\u20118","DOI":"10.1038\/nrc1074","article-title":"5-fluorouracil: mechanisms of action and clinical strategies","volume":"3","author":"Longley","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.dld.2026.04.016_bib0002","first-page":"733\u201143","article-title":"Capecitabine: fulfilling the promise of oral chemotherapy","volume":"3","author":"Hwang","year":"2002","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.dld.2026.04.016_bib0003","doi-asserted-by":"crossref","first-page":"37\u201146","DOI":"10.1016\/j.ejca.2019.09.028","article-title":"Toxicities associated with chemotherapy regimens containing a fluoropyrimidine: a real-life evaluation in France","volume":"124","author":"Barin-Le Guellec","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.dld.2026.04.016_bib0004","first-page":"229\u201163","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"21","key":"10.1016\/j.dld.2026.04.016_bib0005","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.2001.19.21.4097","article-title":"Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study","volume":"19","author":"Van Cutsem","year":"2001","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.dld.2026.04.016_bib0006","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1200\/JCO.2007.11.2144","article-title":"Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803","volume":"25","author":"Saltz","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2026.04.016_bib0007","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/bjc.2017.94","article-title":"Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity","volume":"116","author":"Meulendijks","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.dld.2026.04.016_bib0008","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.ejca.2003.12.004","article-title":"Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil","volume":"40","author":"van Kuilenburg","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.dld.2026.04.016_bib0009","doi-asserted-by":"crossref","first-page":"397\u2011407","DOI":"10.1016\/j.bulcan.2018.02.001","article-title":"Dihydropyrimidine d\u00e9hydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: update and recommendations of the French GPCO-Unicancer and RNPGx networks]","volume":"105","author":"Loriot","year":"2018","journal-title":"Bull Cancer"},{"key":"10.1016\/j.dld.2026.04.016_bib0010","unstructured":"Recherche de d\u00e9ficit en dihydropyrimidine d\u00e9shydrog\u00e9nase en vue de pr\u00e9venir certaines toxicit\u00e9s s\u00e9v\u00e8res survenant sous traitement comportant des fluoropyrimidines [Internet]. [accessed 3 january 2026]. Available on: https:\/\/www.cancer.fr\/catalogue-des-publications\/recherche-de-deficit-en-dihydropyrimidine-deshydrogenase-en-vue-de-prevenir-certaines-toxicites-severes-survenant-sous-traitement-comportant-des-fluoropyrimidines"},{"key":"10.1016\/j.dld.2026.04.016_bib0011","doi-asserted-by":"crossref","first-page":"3\u201117","DOI":"10.1016\/j.ejca.2022.11.028","article-title":"Current diagnostic and clinical issues of screening for dihydropyrimidine dehydrogenase deficiency","volume":"181","author":"Etienne-Grimaldi","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.dld.2026.04.016_bib0012","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/s41416-023-02517-2","article-title":"Dihydropyrimidine dehydrogenase gene variants for predicting grade 4-5 fluoropyrimidine-induced toxicity: FUSAFE individual patient data meta-analysis","volume":"130","author":"Le Teuff","year":"2024","journal-title":"Br J Cancer"},{"key":"10.1016\/j.dld.2026.04.016_bib0013","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/s41416-020-0962-z","article-title":"A comprehensive population-based study comparing the phenotype and genotype in a pretherapeutic screen of dihydropyrimidine dehydrogenase deficiency","volume":"123","author":"Pallet","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.dld.2026.04.016_bib0014","doi-asserted-by":"crossref","first-page":"1639\u20111650","DOI":"10.1016\/S1470-2045(15)00286-7","article-title":"Clinical relevance of DPYD variants c.1679T>G, c.1236G>A\/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data","volume":"16","author":"Meulendijks","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.dld.2026.04.016_bib0015","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ejca.2015.11.008","article-title":"Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: ready for prime time","volume":"54","author":"Lunenburg","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.dld.2026.04.016_bib0016","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1093\/annonc\/mdx411","article-title":"DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update","volume":"28","author":"Henricks","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dld.2026.04.016_bib0017","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/cpt.911","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update","volume":"103","author":"Amstutz","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dld.2026.04.016_bib0018","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S1470-2045(18)30686-7","article-title":"DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis","volume":"19","author":"Henricks","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.dld.2026.04.016_bib0019","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1002\/ijc.32022","article-title":"Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: a matched pair analysis","volume":"144","author":"Henricks","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.dld.2026.04.016_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115483","article-title":"Dose-individualisation of fluoropyrimidines based on pre-treatment serum uracil levels: the Alpe2U study","volume":"224","author":"Knikman","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.dld.2026.04.016_bib0021","doi-asserted-by":"crossref","first-page":"416","DOI":"10.3390\/ph13110416","article-title":"Association of 5-FU therapeutic drug monitoring to DPD phenotype assessment may reduce 5-FU under-exposure","volume":"13","author":"Dolat","year":"2020","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.dld.2026.04.016_bib0022","unstructured":"Health products Regulatory Authority. Summary of Product Characteristics."},{"key":"10.1016\/j.dld.2026.04.016_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101577","article-title":"Impact of renal impairment on dihydropyrimidine dehydrogenase (DPD) phenotyping","volume":"8","author":"Royer","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.dld.2026.04.016_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2023.117326","article-title":"Screening for dihydropyrimidine dehydrogenase deficiency by measuring uracilemia in chronic kidney disease patients is associated with a high rate of false positives","volume":"543","author":"Narjoz","year":"2023","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.dld.2026.04.016_bib0025","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221148536","article-title":"Renal impairment and abnormal liver function tests in pre-therapeutic phenotype-based DPD deficiency screening using uracilemia: a comprehensive population-based study in 1138 patients","volume":"15","author":"Callon","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.dld.2026.04.016_bib0026","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/bcp.15536","article-title":"Quantitative impact of pre-analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiency","volume":"89","author":"Maillard","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.dld.2026.04.016_bib0027","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.annonc.2022.04.073","article-title":"Clinical considerations for DPD deficiency testing in advanced cancer patients: tumor lysis syndrome should be considered as a major interference","volume":"33","author":"Launay","year":"2022","journal-title":"Ann Oncol"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S159086582600722X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S159086582600722X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:44:09Z","timestamp":1785887049000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S159086582600722X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S159086582600722X"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2026.04.016","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dihydropyrimidine dehydrogenase phenotype-guided dose individualization of fluoropyrimidine in gastrointestinal cancers: PRODIGE100-UCGI48-FUDOSE phase II study","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2026.04.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of Editrice Gastroenterologica Italiana S.r.l.","name":"copyright","label":"Copyright"}]}}